In utero analysis of fetal growth: a sonographic weight standard.

Radiology ◽  
1991 ◽  
Vol 181 (1) ◽  
pp. 129-133 ◽  
Author(s):  
F P Hadlock ◽  
R B Harrist ◽  
J Martinez-Poyer
Keyword(s):  
Fetal Growth ◽  
In Utero

scholarly journals 213: Comparison of buprenorphine versus methadone exposure in utero on fetal growth indices and neonatal abstinence syndrome

2018 ◽  
Vol 218 (1) ◽  
pp. S141 ◽  
Author(s):  
Carol C. Coulson ◽  
Erin Lorencz ◽  
Melinda A. Ramage ◽  
Marie Gannon ◽  
Shelley Galvin
Keyword(s):  
Fetal Growth ◽  
In Utero ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Growth Indices

scholarly journals Feeding Your Baby In Utero: How the Uteroplacental Circulation Impacts Pregnancy

Physiology ◽  
2017 ◽  
Vol 32 (3) ◽  
pp. 234-245 ◽  
Author(s):  
Joanna L. James ◽  
Lawrence W. Chamley ◽  
Alys R. Clark
Keyword(s):  
Computational Modeling ◽  
Fetal Growth ◽  
Circulatory System ◽  
In Utero ◽  
Knowledge Gaps ◽  
Nutrient Exchange ◽  
Modeling Approaches

The utero-placental circulation links the maternal and fetal circulations during pregnancy, ensuring adequate gas and nutrient exchange, and consequently fetal growth. However, our understanding of this circulatory system remains incomplete. Here, we discuss how the utero-placental circulation is established, how it changes dynamically during pregnancy, and how this may impact on pregnancy success, highlighting how we may address knowledge gaps through advances in imaging and computational modeling approaches.

scholarly journals ASSOCIATION OF IN UTERO ORGANOCHLORINE PESTICIDE EXPOSURE AND FETAL GROWTH AND LENGTH OF GESTATION IN AN AGRICULTURAL POPULATION

Epidemiology ◽  
2005 ◽  
Vol 16 (5) ◽  
pp. S102
Author(s):  
L Fenster ◽  
B Eskenazi ◽  
M Anderson ◽  
A Bradman ◽  
A Hubbard ◽  
...  
Keyword(s):  
Organochlorine Pesticide ◽  
Fetal Growth ◽  
Pesticide Exposure ◽  
In Utero ◽  
Length Of Gestation

Endocrine regulation of fetal growth

1995 ◽  
Vol 7 (3) ◽  
pp. 351 ◽  
Author(s):  
AL Fowden
Keyword(s):  
Gene Expression ◽  
Growth Factors ◽  
Fetal Growth ◽  
Growth Regulation ◽  
Fetal Liver ◽  
In Utero ◽  
Tissue Differentiation ◽  
Late Gestation ◽  
Endocrine Regulation ◽  
Tissue Accretion

Hormones have an important role in the control of fetal growth. They act on both tissue accretion and differentiation and enable a precise and orderly pattern of growth to occur during late gestation. In part, their actions on growth may be mediated by other growth factors such as the insulin-like growth factors (IGFs). Insulin stimulates fetal growth by increasing the mitotic drive and nutrient availability for tissue accretion. It has little effect on tissue differentiation. In contrast, the main effects of cortisol in utero are on tissue differentiation and maturation. Cortisol appears to act directly on the cells to alter gene transcription or post-translational processing of the gene products. Cortisol may also initiate the transition from the fetal to the adult modes of growth regulation by inducing the switch from IGF-II to IGF-I gene expression in the fetal liver. Thyroxine affects both tissue accretion and differentiation in the fetus by a combination of metabolic and non-metabolic mechanisms. Pituitary growth hormone, on the other hand, appears to have little part in the control of fetal growth, unlike its role postnatally. Fetal hormones, therefore, promote growth and development in utero by altering both the metabolism and gene expression of the fetal tissues. These hormonal actions ensure that fetal growth rate is commensurate with the nutrient supply and that prepartum maturation occurs in preparation for extrauterine life.

scholarly journals DIAGNOSING PREGNANCY, IN UTERO LITTER SIZE, AND FETAL GROWTH WITH ULTRASOUND IN WILD, FREE-RANGING WOLVES

2006 ◽  
Vol 87 (1) ◽  
pp. 85-92 ◽  
Author(s):  
Mark E. McNay ◽  
Thomas R. Stephenson ◽  
Bruce W. Dale
Keyword(s):  
Litter Size ◽  
Fetal Growth ◽  
In Utero ◽  
Free Ranging

scholarly journals Outcomes of Neonates Exposed to Buprenorphine versus Methadone in Utero: A Systematic Review and Meta-Analysis of Safety in the Fetus and Neonate

2021 ◽  
Vol 2 (4) ◽  
pp. 185-194
Author(s):  
Hannah L. Christianson ◽  
Alea A. Sabry ◽  
Jinan E. G. Sous ◽  
Jacquelyn H. Adams ◽  
Kara K. Hoppe ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Fetal Growth ◽  
Controlled Trial ◽  
Academic Research ◽  
In Utero ◽  
P Value ◽  
Randomized Controlled ◽  
Growth Outcomes ◽  
Observational Cohort ◽  
Buprenorphine Treatment

We assessed the prevalence of neonatal abstinence syndrome (NAS) and fetal growth outcomes in neonates exposed to methadone compared to buprenorphine in utero. Three authors assessed the titles and abstracts of all potentially eligible studies. The selection criteria were randomized controlled trials and observational cohort studies from January 2000 to January 2020 which indexed and reported original data for occurrence of NAS and fetal growth outcomes in pregnant people who received methadone vs. buprenorphine treatment. The quality and possible bias of each study was assessed using the Cochrane-risk-of-bias tool. Data were pooled to compare the occurrence of NAS and fetal growth restriction among women who received methadone vs. buprenorphine treatment. Of the 106 articles screened, 1 randomized controlled trial and 5 observational cohort studies including 2041 pregnancies fulfilled the inclusion criteria. Buprenorphine is associated with less NAS and improved growth outcomes compared to methadone. (OR = 0.515; p-value < 0.001). Compared to methadone, buprenorphine is associated with less adverse neonatal outcomes in terms of gestational age at birth, birthweight, and head circumference. With the prevalence of NAS continuing to rise, this study adds to the expanding academic research aimed at creating safer treatment protocols.

Sign in / Sign up

Export Citation Format

Share Document